NDC 50242-060

Avastin

Bevacizumab

Avastin is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Bevacizumab.

Product ID50242-060_3580958a-7a01-45c0-8d9c-87d9a3963158
NDC50242-060
Product TypeHuman Prescription Drug
Proprietary NameAvastin
Generic NameBevacizumab
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2004-02-26
Marketing CategoryBLA / BLA
Application NumberBLA125085
Labeler NameGenentech, Inc.
Substance NameBEVACIZUMAB
Active Ingredient Strength100 mg/4mL
Pharm ClassesVascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 50242-060-01

1 VIAL, SINGLE-USE in 1 CARTON (50242-060-01) > 4 mL in 1 VIAL, SINGLE-USE
Marketing Start Date2004-02-26
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 50242-060-10 [50242006010]

Avastin INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA125085
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2019-04-01

NDC 50242-060-01 [50242006001]

Avastin INJECTION, SOLUTION
Marketing CategoryBLA
Application NumberBLA125085
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitML
Marketing Start Date2004-02-26

Drug Details

Active Ingredients

IngredientStrength
BEVACIZUMAB100 mg/4mL

OpenFDA Data

SPL SET ID:939b5d1f-9fb2-4499-80ef-0607aa6b114e
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1657074
  • 1657068
  • 1657066
  • 1657073
  • Pharmacological Class

    • Vascular Endothelial Growth Factor Inhibitor [EPC]
    • Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
    • Vascular Endothelial Growth Factor Inhibitors [MoA]

    NDC Crossover Matching brand name "Avastin" or generic name "Bevacizumab"

    NDCBrand NameGeneric Name
    50242-060Avastinbevacizumab
    50242-061Avastinbevacizumab

    Trademark Results [Avastin]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    AVASTIN
    AVASTIN
    76278294 2981298 Live/Registered
    GENENTECH, INC.
    2001-06-29

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.